Real Human Fat Ex vivo for first-in-human data

SHAPING RESEARCH WITH
REAL HUMAN DATA

INNOVATIVE, ETHICAL, SUBSTAINABLE AND
HUMAN-RELEVANT TISSUE MODELS

Through our patented technology, we deliver accurate human-relevant data for pharmaceutical, dermo-cosmetic and aesthetic medicine applications, addressing the limitations of traditional testing methods.
Learn More

Backed by leading institutions and partners

incubateur PACA
logo-bpifrance
logo-satt sudest
logo-réseau-entreprendre
logo uca idex
logo CNRS
logo ibv
MNCA
logo-eurobiomed
logo-les deeptech_150x150
logo-la-french-tech
logo la french care
RISE CNRS INNOVATION
cosmetic-valley

BRIDGING THE GAP BETWEEN RESEARCH AND CLINICS

First-in-human ex vivo platform
for pharmaceutical research

Traditional testing methods often fail to predict human outcomes accurately. The lack of human-relevant data in the early stages of research not only slows down progress but also increases costs and limits innovation.
We provide a patented 3D ex vivo platform using real human adipose tissue models. This ensures more reliable, human-relevant data for drug development and product testing, reducing the need for animal models and improving translational success.
We deliver precise, reliable data that bridges the gap between preclinical testing and clinical outcomes.
Read More

OUR SOLUTIONS

PHARMACEUTICALS

ADVANCING DRUG DEVELOPMENT WITH HUMAN RELEVANT DATA

Our innovative platform uses real donor-derived adipose tissue models ex vivo to mimic pathological conditions and generate first-in-human data for drug development.
Tailored to target obesity and chronic metabolic diseases, it provides accurate, early-stage insights that reduce failure rates and accelerate clinical success.
Learn More

DERMO-COSMETICS

A unique ex vivo platform
for accurate product testing and claims

Our platform uses real human tissue models to support
dermo-cosmetic, nutraceutical and aesthetic medicine research, enabling precise testing and innovative claims validation.
This human-relevant approach accelerates product development while ensuring more effective and scientifically backed results.
Learn More
Our patented ExAdEx technology overcomes the barriers of human adipose tissue culture for therapeutic and testing purposes.  ExAdEx technology relies on the innate ability of human adipose tissue stem cells to proliferate in response to mechanical stimuli, within a native extracellular matrix that acts as a 3D bioactive support.

From donor-derived human adipose tissue biopsies, ExAdEx technology stimulates a subpopulation of actively proliferating adipose stem cells to expand within native endogenous 3D mini-tissue units retaining full matrix structure, vascular and lymphatic networks, without the addition of exogenous material.

NEWS & UPDATE

Poster session at IFSCC 2024 with Exsymol

Our Collaboration with Exsymol Monaco at the 34th Congress IFSCC Brazil 2024 We are excited to announce that our scientific research work performed in collaboration

octobre 7, 2024
Our news Archives

GET IN TOUCH

We are happy to answer all your questions, discuss your needs and provide you with tailored solutions.
Please contact us and we will answer as soon as possible.
EXADEX-INNOV
Bioincubateur
Institut de Biologie Valrose
28 Avenue de Valombrose
06100 Nice (FRANCE)

Legal mentions

Copyright © 2022 ExAdEx-Innov All rights reserved

KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management